Focus on Anticoagulation Care

Back to articles

Apixaban better than aspirin for patients with AF


The investigational oral factor Xa inhibitor apixaban (Pfizer; Bristol-Myers Squibb) significantly reduced the risk of stroke or systemic embolism compared with aspirin in patients with atrial fibrillation (AF) who were unsuitable candidates for warfarin therapy, according to results published online in the New England Journal of Medicine.


Connolly SJ et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.